Compare the Return on Investment of Pulsed Field Ablation With Conventional Thermal Ablation for Treatment of Atrial Fibrillation in China
Author(s)
Youqi Fan, PhD1, Ye Wang, PhD2, Yue Gao, MPH3, Yifei Jian, MS3, Shuting Chen, MS3, Jianwei Xuan, PhD3, Hesheng Hu, PhD2.
1Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China, 3Health Economics Institute, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
1Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China, 3Health Economics Institute, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Presentation Documents
OBJECTIVES: To calculate the return-on-investment (ROI) for pulsed field ablation as compared with conventional thermal ablation for treatment of atrial fibrillation.
METHODS: Ablation cost and health resource use data were collected from two tier-three hospitals in China. Diagnosis Related Group (DRG) payments for percutaneous cardiac ablation with atrial fibrillation were collected from government published data for different regions in China. Ablation durations were collected from published literature. Costs and revenues for pulsed field, radiofrequency and cryo-balloon ablation were calculated from hospital payer perspective. ROI was measured by taking the difference between revenue and cost, and dividing by ablation cost. Revenue takes both DRG payment and profit gained by shortened ablation duration into account.
RESULTS: The ROIs for the pulsed field ablation, radiofrequency ablation and cryo-balloon ablation respectively averaged 45.16%, 38.81% and 40.46% across 8 cities over China. In other word, the time saving by shifting from radiofrequency to pulsed filed could bring extra benefit ranging between ￥2749 to ￥4431 (mean: ￥3397, SD: ￥511 ) per case of atrial fibrillation treatment to hospital, while the time saving by shifting from cryo-balloon to pulsed filed could bring extra benefit ranging between ￥2037 to ￥3283 (mean: ￥2517, SD: ￥379) per case to hospital.
CONCLUSIONS: Pulsed field ablation could bring extra financial benefits for treatment of atrial fibrillation by demonstrated shortened ablation duration comparing with conventional thermal ablation.
METHODS: Ablation cost and health resource use data were collected from two tier-three hospitals in China. Diagnosis Related Group (DRG) payments for percutaneous cardiac ablation with atrial fibrillation were collected from government published data for different regions in China. Ablation durations were collected from published literature. Costs and revenues for pulsed field, radiofrequency and cryo-balloon ablation were calculated from hospital payer perspective. ROI was measured by taking the difference between revenue and cost, and dividing by ablation cost. Revenue takes both DRG payment and profit gained by shortened ablation duration into account.
RESULTS: The ROIs for the pulsed field ablation, radiofrequency ablation and cryo-balloon ablation respectively averaged 45.16%, 38.81% and 40.46% across 8 cities over China. In other word, the time saving by shifting from radiofrequency to pulsed filed could bring extra benefit ranging between ￥2749 to ￥4431 (mean: ￥3397, SD: ￥511 ) per case of atrial fibrillation treatment to hospital, while the time saving by shifting from cryo-balloon to pulsed filed could bring extra benefit ranging between ￥2037 to ￥3283 (mean: ￥2517, SD: ￥379) per case to hospital.
CONCLUSIONS: Pulsed field ablation could bring extra financial benefits for treatment of atrial fibrillation by demonstrated shortened ablation duration comparing with conventional thermal ablation.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE420
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)